Mesenchymal Stromal Cells (MSCs), have been used in cell therapy for treatment of various inflammatory conditions. Chimeric Antigen Receptor (CAR) engineered MSCs have the potential to create an MSCs with higher immunosuppression activity and in-vivo persistence.
PhotonPharma’s Innocell involves sampling a patient’s tumor cells, inactivating them so that they are unable to replicate, then administering them back to the patient.
For patients and doctors battling resistant infections, Validus Cellular Therapeutics is developing VCT-001, a novel preclinical stage anti-infective therapy unlike current small molecule antibiotics, which are susceptible to resistance and are limited accessing infections.
Pulmonary arterial hypertension (PAH) affects 200, 000 people annually and there is no cure for this condition. Researchers at Indiana University and University of Illinois at Chicago, have identified a potential drug for curing PAH.
Vaccines must elicit immune responses of a sufficient magnitude and quality to prevent or treat disease. While existing vaccine technologies are capable of achieving this goal for many diseases, these strategies have thus far proven inadequate against global threats like HIV and cancer.
Pancreatic ductal adenocarcinoma (PDAC) has one of the highest mortalities of all malignancies, with aggressive biology, resistance to therapeutic agents, and a mere 5-year survival of 8-9%.
Inventors at the University of Iowa have developed an RNA-based therapeutic that can be used in medical and dental applications.
B cells are primarily known for their robust adaptive immune response through antibody production; however, they are often overlooked among the body’s professional antigen-presenting cell (APC) populations.
Therapeutic proteins have been used to successfully treat a variety of neurodegenerative diseases.